Trial Profile

Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 12 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abemaciclib (Primary) ; Alpelisib (Primary) ; Atezolizumab (Primary) ; Binimetinib (Primary) ; Cobimetinib (Primary) ; Dabrafenib (Primary) ; Encorafenib (Primary) ; Nivolumab (Primary) ; Olaparib (Primary) ; Palbociclib (Primary) ; Pembrolizumab (Primary) ; Ribociclib (Primary) ; Talazoparib (Primary) ; Trametinib (Primary) ; Vemurafenib (Primary)
Indications Cancer
Focus Adverse reactions; Expanded access
Acronyms TAILOR

Most Recent Events

08 May 2023 Status changed from recruiting to discontinued.
08 Jun 2021 Planned initiation date (estimated date of first participant enrollement) changed from 1 Apr 2021 to 30 Jun 2021.
08 Jun 2021 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com